Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
Friday
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health | FMCG | Executive
         
Latest Jobs
Exclusive vacancies may not be shown here, please contact Ben on +44 1494 818005 or Ben@zenopa.com for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Ben Chadwick
Team Leader
Ben@zenopa.com
+44 1494 818005

Testimonials
I want to thank Zenopa for their time and efforts in helping me during my job search, you have given me the extra confidence I need to keep me pro-active in my search.
Mohammed, 2011

Almirall makes $15m equity investment in Ironwood

11 November 2009 00:00 in Pharmaceutical Company Product News


Almirall, which holds the European rights to the irritable bowel syndrome treatment linaclotide, has made a payment of $15 million (8.9 million pounds) to Ironwood as part of an earlier agreement.

An exiting exclusive licensing contract for linaclotide announced last May stipulated that Almirall will be responsible for the commercialisation of this compound in member states of the EU.

The payment comes after the positive outcome of a phase III trial into the drug.

Linaclotide is a therapy for the treatment of irritable bowel syndrome with constipation, as well as chronic constipation.

Eduardo Sanchiz, chief executive for corporate development and finance at Almirall, stated: "We are very pleased with this investment which reflects the good progression of linaclotide, a very significant asset in our pipeline."

Last month, Almirall posted the latest developments in trials around its chronic obstructive pulmonary disease therapy Eklira (aclidinium bromide), revealing that the treatment yielded positive results during testing.

Other news stories from 11/11/2009

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Adfero News Agency



   
© Copyright 2013 Zenopa Ltd